XIPERE: payments to doctors
Payments that named XIPERE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 1,880
- Transactions
- 5,551
- Average per transaction
- $221
The per-transaction average — $221 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,880 providers the average total is $654, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $1,113,281 | 90.6% |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $115,676 | 9.4% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $6 | 0.0% |